Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study.
Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy. f.mangiacapra@unicampus.it
Fabio
F
Mangiacapra
Giuseppe
G
Patti
Emanuele
E
Barbato
Dejan
D
Orlic
Aaron J
AJ
Peace
Andrea
A
D'Ambrosio
Miodrag
M
Ostojic
William
W
Wijns
Germano
G
Di Sciascio
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000077144:Clopidogrel; D004305:Dose-Response Relationship, Drug; D006801:Humans; D038622:Internationality; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000188:drug therapy* / Q000453:epidemiology; D011446:Prospective Studies; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine